Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

HumeCare+ vs Maves

HumeCare+
Graded #366

Lower grade

vs+13.199999999999996
Maves
Graded #89

Higher grade

The verdict

Maves takes it — 71.8/100 to 58.6/100.

Maves grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Maves, operating under parent company Homera Health, is a performance-framed telehealth platform offering compounded semaglutide and tirzepatide for weight loss plus sermorelin for anti-aging, with…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMaves +30
54
84
Dose & formulationMaves +13
52
65
Clinical oversightMaves +5
71
76
Labs & monitoringHumeCare+ +1
53
52
FulfillmentMaves +23
64
87
Contract termsHumeCare+ +6
61
55
HumeCare+ · left barMaves · right bar

The numbers

MetricHumeCare+Maves
WeighScore58.6/10071.8/100
GradeCC
Scorecard rank#366#89
Semaglutide$199/mo (starting dose, compounded)$99/mo (starting dose, first-month rate, compounded)
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
HumeCare+

Graded #366 · C

Strengths

  • Pairs compounded semaglutide with continuous body-composition tracking (lose fat, preserve muscle)
  • Includes a Hume Pod body-composition device at no extra cost
  • From $199/mo, billed monthly, cancel anytime
  • Backed by Hume Health, an established body-composition scale brand
  • Clinician-prescribed and monitored with weekly tracking

Where it loses points

  • Final medication pricing is gated behind an intake quiz
  • Only semaglutide is shown on the marketing site (tirzepatide not confirmed)
  • Prescribing medical group and pharmacy partner not named
  • States of operation not published
  • Not LegitScript-certified (no certification displayed)
Maves

Graded #89 · C

Strengths

  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer
  • $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
  • All 50 states covered, stated explicitly
  • Both brand (Maves) and parent (Homera Health) disclosed for accountability

Where it loses points

  • 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
  • Tirzepatide pricing not stated on the homepage — only listed as an offering
  • Named medical director / clinical leadership not disclosed
  • Refund and cancellation policy not detailed publicly
  • Corporate address and arbitration venue not disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard